---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-003183"
form_type: "8-K"
ticker: "EDSA"
cik: "0001540159"
company_name: "Edesa Biotech, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:39:58.224137+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Edesa Biotech reports Q2 net loss of $1.6M; advances vitiligo drug EB06 to Phase 2

## Summary
- Net loss of $1.6M ($0.30/share) vs $1.9M ($0.58) in prior-year Q2; operating expenses fell to $1.6M.
- Completed $15M equity financing from institutional investors; cash and equivalents total $13.9M.
- EB06 Phase 2 IND submission to FDA expected H2 2025; topline results 12-18 months after clearance.
- EB05 ARDS study fully funded by government; R&D spend shifted from EB05 to EB06 program.

## SEC filing metadata
- accession: 0001171843-25-003183
- form_type: 8-K
- ticker: EDSA
- cik: 0001540159
- company_name: Edesa Biotech, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/0001171843-25-003183-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1540159/000117184325003183/f8k_051425.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-003183
- JSON: https://secwatch.observer/filing/0001171843-25-003183.json
- Plain text: https://secwatch.observer/filing/0001171843-25-003183.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.